Topics

Calquence (acalabrutinib; AstraZeneca/Acerta) Overview and Product profile Report 2019 – ResearchAndMarkets.com

06:04 EDT 8 Jul 2019 | Biotech 365

DUBLIN–(BUSINESS WIRE)–The “Calquence” report has been added to ResearchAndMarkets.com’s offering. Calquence (acalabrutinib; AstraZeneca/Acerta) is a novel, orally available, second-generation Bruton’s tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Inhibition of the BTK protein prevents the activation of the B-cell antigen … Continue reading

Original Article: Calquence (acalabrutinib; AstraZeneca/Acerta) Overview and Product profile Report 2019 – ResearchAndMarkets.com

NEXT ARTICLE

More From BioPortfolio on "Calquence (acalabrutinib; AstraZeneca/Acerta) Overview and Product profile Report 2019 – ResearchAndMarkets.com"

Quick Search

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...